[go: up one dir, main page]

WO2000052165A3 - Compositions et methodes de therapie et de diagnostic du cancer du sein - Google Patents

Compositions et methodes de therapie et de diagnostic du cancer du sein Download PDF

Info

Publication number
WO2000052165A3
WO2000052165A3 PCT/US2000/005431 US0005431W WO0052165A3 WO 2000052165 A3 WO2000052165 A3 WO 2000052165A3 US 0005431 W US0005431 W US 0005431W WO 0052165 A3 WO0052165 A3 WO 0052165A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
diagnosis
breast cancer
methods
breast tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/005431
Other languages
English (en)
Other versions
WO2000052165A2 (fr
Inventor
Michael J Lodes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Priority to AU33912/00A priority Critical patent/AU3391200A/en
Publication of WO2000052165A2 publication Critical patent/WO2000052165A2/fr
Publication of WO2000052165A3 publication Critical patent/WO2000052165A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des compositions et des méthodes de thérapie et de diagnostic du cancer, tel que le cancer du sein. Les compositions peuvent contenir un ou plusieurs antigènes de tumeur du sein, des parties immunogènes de ceux-ci ou des polynucléotides qui codent pour ces parties. Dans un autre mode de réalisation, une composition thérapeutique peut contenir une cellule présentant un antigène qui exprime un antigène de tumeur du sein, ou une cellule T spécifique de cellules exprimant un antigène de tumeur du sein. Ces compositions peuvent être utilisées, par exemple, pour prévenir et traiter des maladies telles que le cancer du sein. L'invention concerne également des méthodes diagnostiques basées sur la détection d'un antigène de tumeur du sein dans un échantillon.
PCT/US2000/005431 1999-03-04 2000-02-29 Compositions et methodes de therapie et de diagnostic du cancer du sein Ceased WO2000052165A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU33912/00A AU3391200A (en) 1999-03-04 2000-02-29 Compositions and methods for breast cancer therapy and diagnosis

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US26250599A 1999-03-04 1999-03-04
US09/262,505 1999-03-04
US27288699A 1999-03-19 1999-03-19
US09/272,886 1999-03-19
US39631399A 1999-09-17 1999-09-17
US09/396,313 1999-09-17

Publications (2)

Publication Number Publication Date
WO2000052165A2 WO2000052165A2 (fr) 2000-09-08
WO2000052165A3 true WO2000052165A3 (fr) 2001-02-15

Family

ID=27401517

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/005431 Ceased WO2000052165A2 (fr) 1999-03-04 2000-02-29 Compositions et methodes de therapie et de diagnostic du cancer du sein

Country Status (2)

Country Link
AU (1) AU3391200A (fr)
WO (1) WO2000052165A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL211151B1 (pl) 2000-10-18 2012-04-30 Glaxosmithkline Biolog Sa Kompozycja immunogenna oraz zastosowanie połączenia saponiny, oligonukleotydu immunostymulującego i lipopolisacharydu
US20040166500A1 (en) * 2001-01-16 2004-08-26 Panzer Scott R Secretory molecules
EP1227106A1 (fr) * 2001-01-26 2002-07-31 Boehringer Ingelheim International GmbH Protéines proapoptotiques et de molécules d'ADN codant ces protéines
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US20050118582A1 (en) * 2001-07-12 2005-06-02 Anita Swarnakar Nucleic acid-associated proteins
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7544767B2 (en) * 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
US7723018B2 (en) * 2002-08-30 2010-05-25 Rigel Pharmaceuticals, Incorporated Methods of assaying for cell cycle modulators using components of the ubiquitin ligation cascade
EP1694852B1 (fr) 2003-11-17 2010-10-13 Crusade Laboratories Limited Virus mutant de l'herpes simplex et son utilisation pour traiter le carcinome spinocellulaire
CN101044164A (zh) 2004-07-20 2007-09-26 健泰科生物技术公司 血管生成素样4蛋白抑制剂，组合，以及其用途
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
WO2006014678A2 (fr) 2004-07-20 2006-02-09 Genentech, Inc. Compositions et methodes d'utilisation de la proteine 4 analogue a l'angiopoietine
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2007125621A1 (fr) * 2006-04-28 2007-11-08 Osaka University Nouvelle utilisation d'un gene dont l'expression augmente dans l'îlot pancréatique hyperplastique
US20100247528A1 (en) * 2007-09-06 2010-09-30 Kent Hunter Arrays, kits and cancer characterization methods
AU2015202486B2 (en) * 2008-09-03 2017-09-14 Duke University Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma
AU2013201554B2 (en) * 2008-09-03 2015-02-12 Duke University Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma
MX343226B (es) 2008-09-03 2016-10-28 The Johns Hopkins Univ * Alteraciones geneticas en isocitrato-deshidrogenasa y otros genes en glioma maligno.
CN103038258B (zh) 2010-05-06 2017-02-15 诺华股份有限公司 用于治疗低密度脂蛋白相关蛋白质6(lrp6)的抗体的组合物及使用方法
CA2798390A1 (fr) 2010-05-06 2011-11-10 Novartis Ag Compositions et methodes d'utilisation d'anticorps multivalents therapeutiques de faible densite de la proteine apparentee a la lipoproteine 6 (lrp6)
CA2854457A1 (fr) 2011-11-04 2013-05-10 David Jenkins Constructions de proteine 6 liee a la lipoproteine de basse densite (lrp6) prolongeant leur demi-vie

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997025426A2 (fr) * 1996-01-11 1997-07-17 Corixa Corporation Compositions et procedes pour le traitement et le diagnostic du cancer du sein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997025426A2 (fr) * 1996-01-11 1997-07-17 Corixa Corporation Compositions et procedes pour le traitement et le diagnostic du cancer du sein

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 14 May 1999 (1999-05-14), HATTORI M ET AL: "Homo sapiens genomic DNA, chromosome 21q22.1, D21S226-AML region, clone f43D11-119B8, segment 9/12.", XP002145644 *
LAROCCA D ET AL: "CLONING AND SEQUENCING OF A COMPLEMENTARY DNA ENCODING A M-R 70000 HUMAN BREAST EPITHELIAL MUCIN-ASSOCIATED ANTIGEN", CANCER RESEARCH, vol. 50, no. 18, 1990, pages 5925 - 5930, XP000929768, ISSN: 0008-5472 *
RACEVSKIS JANIS ET AL: "Cloning of a novel nucleolar guanosine 5'-triphosphate binding protein autoantigen from a breast tumor.", CELL GROWTH & DIFFERENTIATION, vol. 7, no. 2, 1996, pages 271 - 280, XP000938734, ISSN: 1044-9523 *
SCHLOM J ET AL: "STRATEGIES FOR THE DEVELOPMENT OF RECOMBINANT VACCINES FOR THE IMMUNOTHERAPY OF BREAST CANCER", BREAST CANCER RESEARCH AND TREATMENT,US,NIJHOFF, BOSTON, vol. 38, no. 1, 1996, pages 27 - 39, XP000578043, ISSN: 0167-6806 *

Also Published As

Publication number Publication date
AU3391200A (en) 2000-09-21
WO2000052165A2 (fr) 2000-09-08

Similar Documents

Publication Publication Date Title
WO2001040269A3 (fr) Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
WO2000060076A3 (fr) Compositions pour le traitement et le diagnostic du cancer du sein et leurs procedes d'utilisation
WO2001025272A3 (fr) Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2001000828A3 (fr) Compositions et techniques de therapie et de diagnostic du cancer du poumon
WO2000004149A3 (fr) Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2001034802A3 (fr) Compositions et methodes de traitement et de diagnostic du cancer de la prostate
WO2001096388A8 (fr) Compositions et procedes servant a traiter et a diagnostiquer le cancer du colon
WO2000052165A3 (fr) Compositions et methodes de therapie et de diagnostic du cancer du sein
WO2001096390A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer du colon
WO2000060077A3 (fr) Composes utilises dans la therapie et le diagnostic du cancer du poumon et methodes d'utilisation
WO2001079286A3 (fr) Compositions et procedes de traitement et de diagnostic du cancer du sein
WO2001075171A3 (fr) Methodes, compositions et necessaires correspondants servant au depistage et a la surveillance du cancer du sein
WO2001072295A3 (fr) Compositions et methodes pouvant traiter ou diagnostiquer le cancer du poumon
WO2000037643A3 (fr) Composes destines a l'immunotherapie et au diagnostic du cancer du colon et methodes d'utilisation
WO2002004514A8 (fr) Compositions et procedes pour le traitement et le diagnostic du cancer du poumon
WO2001073027A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer du colon
WO2001049716A3 (fr) Composes pour l'immunotherapie et le diagnostic du cancer du colon et procedes d'utilisation
WO2001077168A3 (fr) Compositions et procedes permettant de traiter et de diagnostiquer le cancer du poumon
WO2003013431A3 (fr) Compositions et techniques de therapie et de diagnostic du cancer du sein
WO2000078960A3 (fr) Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
WO2001057207A3 (fr) Compositions et methodes destinees a la therapie et au diagnostic du cancer de l'ovaire
WO2001090152A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer du sein
WO2002000174A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer du poumon
WO2002002623A3 (fr) Compositions et methodes de diagnostic et de traitement du cancer des poumons
WO2001073031A3 (fr) Compositions et methodes destinees au traitement et au diagnostic du cancer de l'ovaire

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase